CWHM-12

Description	in vitro: CWHM 12 demonstrated high potency against all of the five possible β subunit binding partners (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8) in in vitro ligand-binding assays, with somewhat less potency against αvβ5 than against the other αv integrins. in vivo: Treated mice with CCl4 for 3 weeks to establish fibrotic disease and then treated with CWHM 12 or vehicle for the final 3 weeks of CCl4. CWHM12 significantly reduced liver fibrosis even after fibrotic disease had been established. Similar to our findings in the liver, administration of CWHM 12 significantly inhibited progression of pulmonary fibrosis.
Pathways	Angiogenesis/Protein Tyrosine Kinase
Targets	Integrin

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.